Cancer name Colon Carcinoma
Cancer Type COCA
Immunotherapy type Immune Checkpoint Therapy;Immunostimulant OR Targeting Therapy
Treatment anti-PD1 Ab
Drugstatus NA
Drugbank ID NA
Checkpoints PD-1
Signature Type Gene
Signature Oasla
Official Symbol OASL
Mode of action TRAN_D_UP
Description for ‘mode of action’：the ‘mode of action’ for signature is composed of three parts: A_B_C. A describes the level at which the corresponding signature changes, it may contain the following values: TRAN(translation), PROT(protein), CE(cell), METH(methylation), AC(acetylation), PHOS(phosphorylation), MU(mutation), SNP(single nucleotide polymorphism), GLYC(glycosylation) and PATH(pathway). B describes the corresponding signature in which cancer immunotherapy condition group has changed, it may contain the following values: R (immunotherapy response group), NR(immunotherapy non-response group), D (Immunotherapy group), ND (No immunotherapy group). C describes the change detail (specific direction) of the corresponding signature, it may contain the following values: UP (High gene/protein expression or increased cellular abundance or enhanced epigenetic modification), DN (Low gene/protein expression or reduced cellular abundance or attenuated epigenetic modifications), LOSS (deletion mutation), GAIN (gain mutation)，Other. For example, the search/browse detail result for CD274 was “PROT_R_UP”, it can be interpreted that the protein level of CD274 was upregulated in immunotherapy response individuals.
Experimental Mouse model
Description There were 15 type I IFN–stimulated genes (deter-mined from pathway analysis) that were significantly upregulated (>2-fold; P < 0.01) in the dinaciclib and combination groups. Similar to the in vitro data, the majority of these genes, including Ifnb1, Oas1g, Oas3, Mx1, Oas1a, Irf7, IsG15, Xaf 1, and Rsad2, mediate antiviral immunity, cytokine production, and immune cell activation and function. None of these type I IFN response genes was significantly upregulated in the anti-PD1 monotherapy group (P > 0.01 vs. the control group), demonstrating that dinaciclib drives a type I IFN response within the tumor shortly after treatment and independently of anti-PD1 treatment.
PMID 29337311
Title Dinaciclib induces immunogenic cell death and enhances anti-PD1–mediated tumor suppression